Adial Pharmaceuticals, Inc. (ADIL) vs VistaGen Therapeutics, Inc. (VTGN)

A side-by-side comparison of Adial Pharmaceuticals, Inc. and VistaGen Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ADIL vs VTGN

growth of $100 · dividends reinvested · last 8y
ADIL -99.8% (-54.9%/yr)VTGN -99.4% (-46.8%/yr)VTGN compounded faster over this window
050100150200250Start $1002020202220242026$0$1
ADIL VTGN

ADIL vs VTGN: by the numbers

  • •VTGN is the larger company ($11M vs $10M market cap).
  • •Both run net losses; ADIL's is the smaller (0.00% vs -2702.64% net margin).

Metrics side by side

Valuation

MetricADILVTGN
P/S ratioN/A4.44
P/B ratioN/A0.45

Profitability

MetricADILVTGN
Gross margin0.00%100.00%
Operating margin0.00%-5683.69%
Net margin0.00%-2702.64%
ROE-37052.06%-276.21%
ROIC-240.64%-275.74%

Growth (annualized)

MetricADILVTGN
Revenue CAGR (5Y)N/A11.63%
Total return CAGR (5Y)-71.86%-68.35%

Frequently asked

How have ADIL and VTGN total returns compared?
Over the past 5 years, ADIL delivered -71.86% and VTGN delivered -68.35% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.